MPN Specialists in the United States - Doctor Reviewed, and frequently updated. It is very … Learn More
September 15, 2023 Ojjaara (momelotinib) approved in the US as the first and only treatment indicated for myelofibrosis patients with anemia Approval is for use in myelofibrosis patients with anemia regardless of prior myelofibrosis therapy Nearly all myelofibrosis patients are estimated to develop anemia over the course of the disease, and over 30% will discontinue […]
Abstract Background Exercise therapy during cancer treatment reduces symptom burden and improves quality of life (QoL). Polycythemia vera (PV) is a myeloproliferative neoplasia associated with good overall survival (up to decades) but a significant symptom burden, including thromboembolic events and dysesthesias. There are no specific exercise recommendations for patients with PV. Thus, we aimed to […]
by David Wallace A disease modifying drug for MPN patients specifically targets disease-initiating stem cells that lead to MPN phenotypes, leading to regression of the disease while improving associated complications. Our guest MPN expert is Dr. Ghaith Abu-Zeinah from Weill Cornell Medicine in NYC. Listen in to learn more.
PV Reporter and MPN Cancer Connection founder David Wallace is interviewed on “PV Pod: Stories from the Marrow.” In the newly released podcast, we shed light on MPN self-advocacy and education on myeloproliferative neoplasms. Helpful tips from the podcast: “It’s normal to be depressed and angry about the situation. I think seeking help is very […]
Abstract Background Pruritus is a frequent symptom experienced by patients with myeloproliferative neoplasms (MPN). Aquagenic pruritus (AP) is the most common type. The Myeloproliferative Neoplasm-Symptom Assessment Form Total Symptom Score (MPN-SAF TSS) self-report questionnaires were distributed to MPN patients before consultations. Objectives The aim of this study was to assess clinical incidence (phenotypical evolution and […]